Introduction
Retroviral insertional mutagenesis in BXH2 and AKXD recombinant inbred (RI) mice induces a high incidence of myeloid leukemia and the proviral integration sites in the leukemias provide powerful genetic tags for disease gene identi®cation (Bedigian et al., 1984; Gilbert et al., 1993) . During the past several years, a number of disease genes have been identi®ed in these leukemias by proviral tagging. They include a tumor suppressor gene, neuro®bromatosis type 1 (Nf1); a gene with homology to the lymphoid-restricted type II membrane protein Jaw1, Mrv integration site 1 (Mrvi1); a gene encoding a hematopoietic cell growth and dierentiation factor, myeloblastosis oncogene (Myb); three homeobox genes, homeobox A7 (Hoxa7), homeobox A9 (Hoxa9), and myeloid ecotropic viral integration site 1 (Meis1); a zinc-®nger protein (Evi1); and a gene with homology to the ubiquitin-speci®c protease 8 (Usp8) oncogene and to genes encoding various cell cycle regulatory proteins, ecotropic viral integration site 5 (Evi5) (Buchberg et al., 1990; Viskochil et al., 1990; Shaughnessy et al., 1999; Copeland and Jenkins, 1999; Nakamura et al., 1996a; Morishita et al., 1988; Liao et al., 1997) . Four of the genes are proven or suspected human disease genes: EVI1, NF1 and HOXA9 are causally associated with myeloid leukemia and EVI5 with stage 4S neuroblastoma (Ogawa et al., 1996; Copeland and Jenkins, 1999; Nakamura et al., 1996b; Roberts et al., 1998) , validating the usefulness of this approach for human disease gene identi®cation.
Although proviral tagging has identi®ed many disease genes, it is apparent that several more genes remain to be cloned. This is suggested by the fact only 45% of BXH2 leukemias contain a virally induced mutation in one of the genes identi®ed so far. Disease genes for 55% of BXH2 leukemias remain to be identi®ed. The same is true for human acute myeloid leukemias (AMLs) where the 11 dierent chromosomal translocations and inversions cloned to date are found in only 45% of AMLs (Look, 1997) . Disease genes for 55% of AMLs remain to be identi®ed. Ultimately, it should be possible to use proviral tagging to do a saturation screen for BXH2 disease genes. The expectation is that some of these genes will represent human AML genes that are not easy to clone because they are infrequently involved in human disease or are not marked by a cytologically detectable rearrangement. Given the large number of genes that may remain to be identi®ed, this task could be dicult using conventional proviral tagging approaches, which rely on cloning leukemia-speci®c integration sites into bacteriophage lambda.
With this potential problem in mind, an inverse PCR (IPCR) method for proviral tagging was developed that makes use of automated DNA sequencing and the genetic tools provided by the Mouse Genome Project, which greatly increases the throughput of proviral tagging for disease gene identi®cation. More than 400 proviral integration sites from BXH2 myeloid leukemias (and AKXD T-and B-cell leukemias) were cloned and characterized using this IPCR method (Li et al., 1999) , which lead to the identi®cation of more than 90 new candidate leukemia disease genes (Li et al., 1999) . Nineteen new common integration sites (sites that are targets of viral integration in more than one leukemia) were also identi®ed in these studies and BLAST search and/or chromosome mapping identi®ed candidate disease genes for 12 of these common sites (Li et al., 1999) .
One common integration site identi®ed by the IPCR is Evi27 (Li et al., 1999) . While BLAST searches did not identify a candidate disease gene for Evi27, chromosome mapping studies showed that Evi27 maps to mouse chromosome 14 in a region of human 3p21 homology . This result is interesting because treatment-related 3p21 breaks are often observed in myelodysplastic syndrome (MDS) and AML patients (Shi et al., 1996) and 3p21 is the most frequently deleted region seen in chronic myeloid leukemia (CML) (Johansson et al., 1997) . Further characterization of Evi27 may therefore identify an important human disease gene. In studies described here, we have identi®ed a novel cytokine receptorrelated gene whose expression is upregulated by viral integration at Evi27. Future studies are aimed at determining whether this is a human disease gene.
Results

Cloning and characterization of genomic sequences from the Evi27 locus
Genomic restriction analysis of DNA from two BXH2 leukemias with proviral integrations at Evi27 (N57 [B160] and 15-38374) showed that the integrations in the two leukemias are located about 1.5 kb apart and are oriented in the same transcriptional direction (Figure 1 ). Lambda and P1 clones from the region were then isolated, restriction mapped and exon trapped. Four exon-trapped products were identi®ed. BLAST searches showed that two of the exons were derived from the mouse choline dehydrogenase (Chdh) gene, while one exon was derived from a gene with high homology to the yeast actin-like protein, ARP8 (accession number S67026). The Chdh gene was subsequently positioned *10 kb to the left of the proviral integration sites and in the opposite transcriptional direction (Figure 1 ). Northern analysis showed that Chdh expression is restricted to liver and is not activated in the B160 cell line (a cell line derived from the N57 leukemia that carries a proviral integration at Evi27 (data not shown). The ARP8 homolog was mapped *15 ± 20 kb to the right of the proviral integration sites. Northern analysis showed that this gene is ubiquitously expressed and is not upregulated in B150 leukemia cells (data not shown). On this basis, Chdh and ARP8 were excluded as candidate disease genes.
The fourth exon (p57ET47) showed no signi®cant homology to any sequences in GeneBank. Hybridization studies showed that this exon was contained within lambda clone p57l129 (Figure 1 ), indicating that it was located within 5 ± 20 kb of the proviral integration sites at Evi27. DNA sequence analysis of p57l129 identi®ed a 103 bp fragment that was homologous to a human fetal liver cDNA EST (accession number T96740). This EST sequence was localized 1240 bp upstream of p57ED47 and was found to be oriented in the same transcriptional direction, suggesting that both exons might be derived from the same gene.
Northern blot analysis of mouse tissues using both exons as probes con®rmed this prediction and showed that the Evi27 hybridization pattern is complex. Six dierent Evi27 transcripts of approximately 4.4, 4.2, 2.3, 1.9, 1.3, and 1.1 kb in size, could be detected on Northern blots (Figure 2 ). In adult tissues the expression was seen in liver and testes where the 2.3 and 1.9 kb transcripts predominated. Expression of the 4.2 transcript was also seen in liver and testes. In addition, low levels of the 2.3 and 1.9 kb transcripts Figure 1 A partial long-range restriction map of the Evi27 locus. Bacteriophage l and P1 clones used for gene localization and exon trapping are shown above the map. The location of the 5' end and transcriptional orientation of the Evi27 and Cdhd genes are noted by arrows above the map. The location of the exon with homology to the yeast ARP8 gene is also noted. The transcriptional orientation of this gene has not been determined. The position and transcriptional orientation of the proviruses in the B160 and 15-38374 leukemias are indicated below the map. The cluster of rare cutting restriction enzymes surrounding the proviral integration sites is also noted. The 14 kb BamHI fragment cloned from leukemia B160 is presented below the map. The viral sequences and viral long terminal repeat (LTR) is noted by a thick line and black box, respectively. The position of the 5' end of Evi27 with respect to the viral LTR is noted. Restriction enzymes: B, BamHI; Bs, BssHII; C, ClaI; E, EagI; MluI, N, NaeI; Nr, NruI, S, SacII; Sa, SalI were seen in kidney along (Figure 2a) . With long exposure, the lung showed expression of a 2.1 kb transcript, while the heart showed expression of the 1.3 kb transcript. No expression was seen in skeletal muscle, brain, or spleen.
In addition to adult tissues, Evi27 expression was also detected in some hematopoietic cell lines. These cell lines include the EL-4 T-cell line, which express the 4.2 and 1.3 kb transcripts, the WEHI231 B-cell line which expresses the 4.2, 1.3 and 1.1 kb transcripts, and the R1.1 T-cell line, which expresses the 1.9 kb transcript. In contrast, little or no expression was detected in the 32D, WEHI 3B, and M1 myeloid cell lines, the HYB.548 B-cell line, or the P815 mast cell line (Figure 2c ).
Evi27 expression could also be detected in BXH2 myeloid cell lines whether or not they carry a proviral integration at Evi27. These cell lines expressed. Expression of the 4.4, 4.2, 1.9 and 1.1 kb transcripts was variable among the dierent lines (Figure 2c ), but the highest expression was seen in the B160 cell line, which contains a viral integration at Evi27. In this cell line the 4.4 kb transcript predominated. These results suggest that viral integration at Evi27 results in increased Evi27 expression.
In humans, two EVI27 transcripts, 1.9 and 2.7 kb in size, were detected ( Figure 3 ). Human EVI27 expression is therefore considerably less complex than in mouse. The highest EVI27 expression was seen in kidney (Figure 3a) , while in the mouse, Evi27 was expressed at low levels in the kidney. Moderate expression was also observed in the brain, liver, and testes with low to undetectable expression in lung. No EVI27 expression was seen in heart, placenta, and skeletal muscle (Figure 3a ) or in immune tissues such as spleen, lymph nodes, thymus, peripheral blood lymphocytes, or bone marrow (Figure 3b ). High EVI27 expression was, however, observed in the fetal liver.
Within cell lines, moderate EVI27 expression was seen in the cervical carcinoma HeLa, chronic myelogenous leukemia, K562, and colon adenocarcinoma, Figure 3 Northern blot analyses of EVI27 expression in human tissues and cancer cell lines. Multiple tissue Northern blots of normal adult (a), immune tissues (b) and cancer cell lines (c) hybridized with an EST speci®c for the human EVI27 gene. The human cancer cell lines are HL60, promyelocytic leukemia; HeLa, cervical carcinoma; K562, chronic myelogenous leukemia; MOLT4, Tlymphoblastic leukemia; Raji, Burkitt's lymphoma; SW480, colon adenocarcinoma; A549, lung carcinoma; G361, melanoma. The blots were also hybridized with a b-actin probe to control for RNA loading. The size in kb of molecular weight markers is shown on the left of each panel (Figure 3c) but not in the myeloid leukemia HL-60, acute lymphoblastic T-cell leukemia, MOLT-4, Burkitt's lymphoma, Raji, lung carcinoma, A549 and the melanoma, G361 cell lines.
The gene whose expression is upregulated by viral integration at Evi27 encodes a novel IL17 receptor-related protein
The complete coding region of human gene was obtained by 3', and then 5' RACE. The primary 5' RACE product using primers from the 3' end of the gene was *1.9 kb in length, consistent with the size of the major human transcript. A larger minor species was also produced in the 5' RACE reaction. Sequence analysis showed that it contained an additional 950 bp of sequence that was not present in the 1.9 kb product. PCR and genomic sequence analysis showed that this extra sequence was an unspliced intron. Northern analysis showed that the 2.7 kb human transcript contains this unspliced intron (data not shown) and sequence analysis showed that this unspliced intron introduces multiple stop codons into the open reading frame of the protein.
The sequence of the full length 1.9 and 2.7 kb transcripts has been deposited in GenBank (accession numbers AF208110 and AF208111, respectively). The predicted uninterrupted protein is 502 amino acids (aa) and has a predicted molecular weight of 56 kD ( Figure  4 ). pSORT analysis identi®ed a potential cleavable signal peptide at the N terminus of the protein. A putative transmembrane domain starts at residue 293 and ends at residue 309. The cytoplasmic tail is predicted to extend from residue 310 to the C terminus. pSORT analysis also indicated that the protein has type 1a topology. A string of 39 aa derived from intronic sequences would be inserted at amino acid 250 in the 2.7 kb transcript. This would result in the synthesis of a 288 aa protein with a predicted molecular weight of 31 kD. The transmembrane and cytoplasmic portions of the 502 aa isoform are missing in this truncated form of the protein.
Multiple 5' RACE products were also obtained in mouse. Cloning and sequence analysis of these RACE products showed that they can be created by the inclusion of at least two unspliced introns. As in human, these intron sequences introduce multiple stop codons into the open reading frame of the protein. The sequence of the full length 1.9 and 2.5 kb mouse transcripts has been deposited in GenBank (accession numbers AF208108 and AF208109, respectively). The In the 2.5 kb transcript, a string of 57 novel amino acids, derived from intron 7, is added at aa 162 creating a protein with an open reading frame of 218 aa and a predicted molecular weight of 24 kD. Like the shorter human isoform, this isoform would lack the transmembrane and cytoplasmic domains of the protein.
The full-length human and mouse proteins are 83% similar and 76% identical (Figure 4 ). The extracellular domain of both proteins contains three conserved Nlinked glycosylation and a GSK3 phosphorylation site. A single conserved GSK3 phosphorylation site is also present in the cytoplasmic domain.
Amino acid sequence comparisons showed that Evi27 has signi®cant homology throughout its coding region to the human and mouse IL17 receptor (IL17R) (E value=2.5 e-29) ( Figure 5 ). The position of the transmembrane domain with respect to the amino terminus is essentially the same in the two proteins. However, the cytoplasmic tail of the IL17R is nearly 304 aa longer than that of the Evi27. Although Evi27 is predicted to encode both membrane bound and soluble forms, IL17R is not known to encode a soluble form.
The mouse and human genes map in syntenic regions
The human EVI27 gene was mapped to chromosome 3p21 by¯uorescence in situ hybridization of highresolution G-banded chromosomes (Figure 6 ). These results are consistent with the mouse mapping data, which localize the mouse gene to chromosome 14 in a region of human 3p21 homology (Copeland et al., 1995) . They also con®rm that the human gene maps in a region of the human genome that is frequently rearranged in human myeloid leukemia.
Expression and subcellular localization of Evi27
The expression and subcellular localization of the mouse protein was examined using a polyclonal antibody raised against a conserved peptide derived from the extracellular domain of the N-terminus of Evi27 ( Figure 4 ). Antibody speci®city was con®rmed by Western blot and immuno¯uorescence staining of 32D cells, which express undetectable levels of Evi27 mRNA ( Figure 7b ) and 32D cells stably transfected with a full length 1.9 kb Evi27 cDNA clone. Western blot analysis showed that whereas the parental 32D cells show weak expression of the expected 55 kD full length protein, the transfected line expresses approximately 3 ± 5-fold higher levels of this isoform (data not shown). Immuno¯uorescence analysis showed weak staining in the parental line whereas transfected cells showed more abundant cytoplasmic staining ( Figure  7a ). Clear cell surface staining was observed after analysis of live cells or ®xed, but not permeabilized, transfected cells (data not shown). In all experiments the staining could be quenched by preincubation of the antisera with Evi27 peptide (Figure 7a , right panels). In contrast to the low level expression in the 32D myeloid leukemia line high level of both cytoplasmic and cell surface expression of the protein was noted in the cell line B160 (Figure 8 ). Although several other BXH2 cell lines also showed expression, the highest expression was seen on B160 cells, consistent with Northern results showing that Evi27 mRNA is overexpressed in B160 cells (Figure 2 ).
Western blot analysis of Evi27 protein expression
Western blot analysis of a number of murine leukemia cell lines con®rmed the Northern results and showed that many dierent Evi27 isoforms are expressed at the protein level ( Figure 9 ). A 56 kD protein, which is the predicted size of the full length protein containing the transmembrane and cytoplasmic domains, was expressed in most samples tested (Figure 9a ). The EL4 and R1.1 Tcell lines and the WEHI 231 B-cell line also expresses a 24 kD protein, which is the predicted size of the truncated protein resulting from intron incorporation and an 85 kD protein (Figure 9a ). This protein is also expressed at low levels in the B190 cell line but not in the other BXH2 leukemia cell lines tested.
Several cytokine receptors also produce soluble forms of the receptor by proteolytic cleavage of the membrane bound receptor. The cleavage sites are located near the plasma membrane in the extracellular domain of the receptor. Proteolytic cleavage of the Evi27 membrane receptor in this region is predicted to produce a 33 kD protein. A band of this size is also present in most samples tested (Figure 9a ). Several unexpected sized Evi27 bands were also detected on the Western blot. These protein bands can all be competed away by the addition of Evi27 peptide (Figure 9b ), indicating that they contain authentic Evi27 protein sequences. The origin of these protein bands is unknown but could result from the translation of Evi27 mRNA transcripts that have yet to be sequenced or may be indicative of homo-or heteropolymer formation. The expression of these protein bands is sometimes variable. For example, the 75 kD band is expressed at low or undetectable levels in the B160 and B187 cell lines. The B193 cell line does not express the 150 and 127 kD bands, but does express high levels of the 75 and 33 kD bands. The reason for this is not clear, but may re¯ect the dierentiation state of the cell line. Consistent with this hypothesis, T-and B-cell lines express Evi27 protein bands that are not expressed in BXH2 myeloid cell lines (i.e., 24 and 85 kD bands).
Discussion
In studies described here we show that retroviral integration at the Evi27 locus in BXH2 murine myeloid A number of cytokine receptors (i.e., v-mpl or Tpor, Il6ra, Epor, Il9r, Csf1, Il2ra, Il4ra and Ifngr2) or their ligands (i.e., Il6, Csf1, Il3) are reported targets of retroviral integration or transduction in mouse leukemia/lymphomas making cytokines/cytokine receptors one of the largest and most important classes of leukemia genes (Ymer et al., 1985; Penciolelli et al., 1987; Gisselbrecht et al., 1987; Baumbach et al., 1988; Sugita et al., 1990; Blankenstein et al., 1990; Souyri et al., 1990; Hino et al., 1991; Chretian et al., 1994; Flubacher et al., 1994; Li et al., 1999) . The Evi27-encoded cytokine-related receptor is therefore an excellent candidate for a new leukemia disease gene. The human EVI27 gene was also cloned and mapped to chromosome 3p14-p21, in a region syntenic to the mouse gene. The human protein is 76% identical to the mouse protein at the amino acid level. This is somewhat higher than the recently described homology between the mouse and human IL17 receptors, which are 69% identical at the amino acid level (Yao et al., 1997) . This conservation suggests that Evi27 receptor function is evolutionarily conserved between human and mouse. Proviral integrations at Evi27 are located about 6 kb upstream from the ®rst known exon of the IL17 receptor-related gene and result in increased gene expression. Viral integration at Evi27 may thus induce disease simply by upregulating or constitutively activating receptor expression. However, given the complex expression pattern observed for Evi27, it is also possible the viral integration induces disease by altering Evi27 isoform expression. In the mouse, as many as six Evi27 transcripts are detected on Northern blots. Two of the transcripts result from intron incorporation and are predicted to produce a truncated soluble form of the receptor lacking the transmembrane and cytoplasmic domains. Several cytokine receptors are known to produce soluble as well as membrane bound forms and it is now well documented that the soluble receptors can have both positive and negative eects on ligand signaling (for review see Heaney and Golde, 1996) . The origin of the other Evi27 transcripts has not been determined. It is thus possible that one or more of these uncharacterized messages encode sequences that are located upstream of Evi27 proviral integration sites at Evi27. If this is the case, then Evi27 proviral integrations may prevent these messages from being expressed and this may have important disease consequences.
Il17r/Evi27 receptors are unusual in that they have no homology with any protein in public databases, including other cytokine receptor proteins, and they have no recognizable motifs associated with intracellular signaling (Yao et al., 1995b , data presented here). Many disease-related cytokine receptors involved in leukemogenesis contain kinase domains, however, it is not unprecedented to ®nd receptors lacking kinase domains that are involved in disease. For example, the human MAS1 oncogene, which encodes a functional angiotensin receptor, is a G-protein coupled receptor that functions through phosphatidylinositol 4,5-bisphosphate hydrolysis (Young et al., 1986; Jackson et al., 1988) . Evi27 may thus identify a new disease pathway.
At least seven dierent Evi27 isoforms (i.e., 24, 33, 56, 47, 75, 127 and 150 kD in size) were detected in BXH2 leukemia cell extracts by Western analysis using an Evi27-speci®c antibody. All leukemia extracts expressed the 56 kD isoform (the membrane bound receptor) as well as the 33 kD isoform (a postulated proteolytic cleavage containing the extracellular ligandbinding domain of the receptor). Expression of the other isoforms was variable among the extracts. One of seven cell extracts (B190) expressed the 24 kD isoform (a putative truncated receptor resulting from intron incorporation), three extracts (B139, B160 and B187) express the 47 kD isoform, ®ve extracts (B112, B132, B139, B190, B193) the 75 kD isoform, and six extracts (B112, B132, B139, B160, B187, B190) the 150 kD isoform. The origin of these larger isoforms (i.e., oligomerization) or the reason for their variable expression (i.e. dierentiation state of the cell) is presently unclear. Western blot analysis proteins derived from human cell lines shows that only two isoforms (55 and 29 kD) are produced (data not shown).
Only one BXH2 leukemia cell extract, B160, analysed on Western blots is known to contain a proviral integration at Evi27. The 56 kD isoform is overexpressed in B160 cells, consistent with Northern results showing that viral integration at Evi27 results in increased Evi27 expression. Surprisingly, the 56 kD isoform is also overexpressed in B187 cells, which are not known to carry a viral integration at Evi27. Perhaps, B187 cells harbor a viral integration at Evi27 that maps outside the region examined on Southern blots or there are other mechanisms for upregulating expression of this isoform other than proviral integration. It is interesting to note that B187 cells, like B160 cells, also fail to express the 75 kD isoform. One intriguing possibility is that viral integration at Evi27 blocks expression of this isoform.
Evi27 expression is restricted in the hematopoietic cells. Northern analysis showed that Evi27 is expressed in T cells and ESTs homologous to the mouse gene have been identi®ed in CD4 + T-cells. Likewise, the mouse preB-cell line WEHI231 expresses Evi27 and ESTs homologous to EVI27 have been identi®ed in human germinal center B cells and follicular lymphomas. No Evi27 expression was seen in the late stage Bcell line 548, the Burkitt lymphoma cell line Raji, the murine erythroid line D1b, or the mast cell line P815. A complex pattern of expression was observed within the myeloid compartment. Variable expression was seen in BXH2 leukemia cells, while little or no Evi27 expression was seen in the M1 and 32D murine myeloid leukemia cell lines or in the monocytic leukemia cell line WEHI-3B. Evi27 is expressed, however, in the chronic human myelogenous leukemia cell line K562, but not in the promyelocytic leukemia cell line HL-60. These results suggest that Evi27 expression may be tightly regulated during myeloid cell dierentiation and imply that Evi27 may have an important function in controlling the growth and/or dierentiation of hematopoietic cells. Proviral integration at Evi27 may interfere with this function(s) and, in doing so, lead to myeloid disease. IL17 (CTLA8) is a homodimeric cytokine of about 32 kD expressed exclusively from human memory T cells or mouse alpha beta TCR + CD4 7
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7 thymocytes (Rouvier et al., 1993; Yao et al., 1995a,b; Kennedy et al., 1996) . In contrast with the tightly controlled expression of the ligand, the IL17 receptor is ubiquitously distributed but more abundant in spleen and kidney (Yao et al., 1995b) . Although devoid of direct eects on cells of hematopoietic origin, IL17 induces the secretion of IL6, IL8, PGE2, MCP1 and G-CSF by adherent cells like ®broblasts, keratinocytes, epithelial and endothelial cells (Yao et al., 1995a,b; Fossiez et al., 1996) . When cultured in the presence of IL17, ®broblasts can sustain the proliferation of CD34 + human progenitors and their preferential dierentiation into neutrophils (Fossie et al., 1996) . Adenovirus-mediated transfer of murine IL17 cDNA into liver has also been shown to induce a transient, but dramatic granulopoiesis in vivo, except in IL6-de®cient mice (Schwarzenberger et al., 1998) .
The Evi27 protein is a member of the IL-17 receptor family. Two new members of the IL-17 cytokine family have recently been identi®ed (Li et al., 2000) . These studies have demonstrated that IL-17B and IL-17C do not bind the IL-17 receptor extracellular domain, indicating that IL-17B and IL-17C are likely to bind unique, yet uncharacterized receptors (Li et al., 2000) . In a survey of cytokine induction, IL-17B and IL-17C stimulate the release of TNFa and IL-1b from the monocytic leukemia cell line THP-1 (Li et al., 2000) . RT ± PCR analysis has shown that IL-17B is expressed by both the B160 leukemia and the stromal cell on which it depends (JS, unpublished data). We speculate that Evi27 may represent the receptor for IL-17B or IL-17C. Based on these data a model for Evi27 in myeloid leukemia development is proposed. Terminal dierentiation of myelomonocytic precursor cells likely result in the down regulation of Evi27 expression. However, proviral insertions at Evi27 result in constitutive expression of the receptor. Binding of IL-17B/C to the Evi27 receptor would trigger the release of TNFa and IL-1b by the leukemic cell. The TNFa and IL-1b would in turn provoke the production of multilinage hematopoietic growth factors, adhesion molecules, and in¯ammatory cytokines by stromal cells (Bagby, 1994) . These stromal cell derived factors then support the growth and survival of the leukemia cell and may account for the absolute dependence of the B160 leukemia on the stromal feeder layer for growth and survival.
The human homolog of Evi27 may also be involved in human disease. EVI27 maps to chromosome 3p21, a region consistently deleted in a variety of human cancers. Loss of 3p heterozygosity is also frequently observed in renal cell carcinoma, lung cancer and breast cancer and analysis of 3p allele loss in renal cell cancer has localized a candidate tumor suppressor gene to 3p21 (van den Berg et al., 1997) . These results are consistent with the hypothesis that chromosome 3p encodes a number of tumor suppressor genes. Given that EVI27 maps to 3p21 and is expressed at high levels in normal human kidney, it will be interesting to determine whether this gene is aected by 3p21 mutations in renal cell carcinoma. EVI27 also may be a human myeloid leukemia disease gene. Recurrent treatment-related chromosome 3p21 breaks are frequently observed in myelodysplastic syndrome and acute myeloid leukemia patients (Shi et al., 1996) and 3p21 is the most frequently deleted region in human CML (Johansson et al., 1997) . Future studies will be aimed at determining whether EVI27 is a human myeloid leukemia disease gene.
Materials and methods
BXH2 mice and leukemic cell lines
The BXH2 recombinant inbred strain was obtained from the Jackson Laboratory (Bar Harbor, ME, USA) and maintained at the NCI-Frederick Cancer Research and Development Center. BXH2 leukemia cell lines have been previously described (Largaespada et al., 1995) . Other cell lines were purchased from the ATCC and grown in either RPMI 1640 or DMEM supplemented with 2 mM gluatmine, 4.5 g/L glucose, Pen-Strep, and 10% fetal bovine serum (Atlanta Biologicals, Atlanta, GA, USA).
DNA extraction and Southern blot hybridization
High molecular weight genomic DNAs were extracted from frozen normal tissues and leukemic spleens and lymph nodes as previously described (Jenkins et al., 1982) . Bacteriophage and plasmid DNAs were puri®ed using standard procedures (Sambrook et al., 1987) . Restriction enzyme digestions, agarose gel electrophoresis, Southern blot transfers, hybridizations, and washes were performed as previously described (Sambrook et al., 1987) .
Genomic cloning
Seventy mg of DNA from leukemia N57 was digested to completion with BamHI and fractionated by electrophoresis in TAE buer. Fragments approximating the somatically acquired pAKV5 (ecotropic murine leukemia virus) hybridizing fragments were cut from the gel and puri®ed using Qiaex beads according to the manufacturer's instructions (Qiagen, Valencia, CA, USA). The BamHI fragments were cloned into EMBL4 phage arms (Stratagene, La Jolla, CA, USA). Ligated material was packaged with Gigapack Gold packaging extracts (Stratagene). Library screening was performed according to the protocol of Benton and Davis (1977) . The P1 and lambda genomic clones were derived from commercial libraries (Genome Systems, St Louis, MO, USA; Clontech, Palo Alto, CA, USA).
Human chromosome mapping
Metaphase chromosomes from normal peripheral blood samples were prepared using conventional methods. Slides were incubated in 26SSC (pH 7.0, 378C ) for 15 min then immersed in 0.1 N HCl/0.05% Triton X-100 for 15 min at room temperature (RT). Slides were washed in 26SSC (pH 7.0) twice at RT, then washed in 16PBS, pH 7.2 once at RT. Slides were immersed in 1% formaldehyde (diluted in PBS) for 10 min at RT, washed twice in 16PBS at RT, then once in 26SSC (pH 7.0) at RT. Chromosomes were dehydrated in an ethanol series and air dried at RT. A human PAC clone speci®c for EVI27 was isolated according to the manufacturer's instructions (Genome Systems, St Louis, MO, USA). Spectrum-Red-dUTP (Vysis, Downer's Grove, IL, USA) was incorporated into the PAC probe by nick translation according to the manufacturer's protocol (Vysis). DNA was resuspended in Hybrisol VII (Oncor, Gaithersburg, MD, USA) (50% formamide/26SSC) at a ®nal concentration of 5 ng/ml and hybridized to chromosomes according to manufacturer's instructions. The chromosomes and probe solution was incubated at 758C for 10 min then to 378C for 16 h in a humidi®ed chamber. Post hybridization washes consisted of 65% formamide/26SSC (pH 7.0) for 15 min at 438C, then 26SSC (pH 7.0) for 8 min at 378C , 16PBD (Oncor) twice at RT, then in 16PBS (pH 7.2). Finally, 10 ml of propidium iodide/antifade (1 : 20) was added on each area and a coverslip added. Following FISH the slide was washed twice in Xylene to remove the coverslip and excess oil. The slide was then washed in 16PBD at 378C for 5 min, followed by a dehyrdration step through an ethanol series. The slide was then incubated in 50% formamide/26SSC for 90 min at 378C, washed brie¯y in tap water, followed by dehydration in 10, 80 and 95% ethanol and stained with Wright's stain/phosphate buer for 5 min.
Exon trapping
The P1 clone p57P1 was digested to completion with BglII and BamHI and puri®ed by phenol extractions and ethanol precipitations. Insert DNA was then ligated to a BamHI digested pSPL3 vector (Life Technologies, Gaithersburg, MD, USA). DNA from the ligations was used to transform DH10B maximum eciency cells (Life Technologies). Additional steps in the experiment were performed exactly according to the manufacturers protocol (Life Technologies). DNA sequence of approximately 100 individual clones from each ligation was generated as described below.
Poly(A)
+ RNA isolation and Northern blot analysis
Premade Northern blots containing 2 mg of twice selected poly(A) + RNA from various normal tissues and cell lines were purchased from commercial source (Clontech, Palo Alto, CA, USA). Total RNA was extracted from cell line suspensions by the RNAzol B method (Tel-Test, Friendswood, TX, USA). Poly(A) + RNA was puri®ed from the total RNA preps by oligo-d(T) column chromatography according to the manufacturers recommendations (Amersham Pharmacia Biotech, Piscataway, NJ, USA). Two to ®ve mg of poly(A) + RNA was fractionated by electrophoresis in 1.0% agarose gels containing formaldehyde and transferred to Hybond N + membranes (Amersham Pharmacia Biotech). The membranes were prehybridized and hybridized according to the method of Church and Gilbert or using ExpressHyb solution (Clontech). Blots were then exposed to X-ray ®lm at 7708C with an intensifying screen.
cDNA cloning cDNA cloning was carried out by a combination of 5' and 3' rapid ampli®cation of cDNA ends (5' and 3' RACE) and modi®ed RT ± PCR as described . Brie¯y, the nucleotide sequence of the trapped exon p57P1ET47 was used to design speci®c nested oligonucleotides. The primary 5' and 3' RACE reactions were performed using mouse liver Marathon Ready cDNA (Clontech) as a template according to the manufacturers protocol using the Advantage cDNA ampli®cation kit (Clontech). After cloning and sequencing, nested primers speci®c for the 5' and 3' ends of the gene were synthesized. Another cycle of PCR was performed using Marathon Ready liver cDNA as a template and the full length cDNA was generated by PCR as follows: one cycle: 948C, 1 min; 30 cycles: 948C, 30 s, 688C, 7 min. The products of the reaction were subcloned into pCR2.1 (Invitrogen, Carlsbad, CA, USA) and sequenced. The fulllength cDNA of the 1.9 and 2.7 kb transcripts have been submitted to GenBank under accession numbers AF208108 and AF208109, respectively. Human cDNAs covering the coding region of the EVI27 gene were synthesized in a similar manner as described above. Brie¯y, a human EST (accession number T96740), with high homology to the mouse EVI27 cDNA, was used to design nested oligonucleotide primers at the 5' and 3' end of the EST. 5' and 3' RACE products from Marathon Ready fetal liver cDNA (Clontech) were synthesized as described above. The 1.9 and 2.9 kb human EVI27 cDNA nucleotide sequences are deposited in GenBank under accession numbers AF208110 and AF208111.
Transfection and establishment of stable cell lines The 1.9 kb mouse Evi27 cDNA was cloned into the NotI ± HindIII site of the pcDNA3.1(7) eukaryotic expression vector and transformed into DH5a bacteria. Ten mg of recombinant plasmid DNA was resuspended at 1 mg/ml in sterile TE. Cell lines 32Dc13, M1, WEHI3B and NIH3T3 were grown in appropriate media maintaining cell viability at 90%. Cells were harvested and washed 36in FBS-free DMEM media. Cells were resuspended at 5610 6 cells per ml in FBS-free DMEM. One ml of the cell suspension was mixed with DEAE dextran at 0.1 mg/ml and 10 mg of plasmid DNA in an 0.4 cm electrode gap electroporation cuvette and chilled on ice for 10 min and Electroporated at 270 V/975 mF in a Gene Pulser II (Bio-Rad, Hurcules, CA, USA). The cuvette was chilled on ice for 10 min then the cells were transferred into 10 ml of fresh media and grown for 72 h. G418 selection was carried out in 2 mg/ml for 2 weeks. Limiting dilution cloning in 96 well culture dishes was performed at 1 mg/ml G418 on all cell lines with the exception of NIH3T3. Stable transfectants were cloned and tested for expression of the transgene by Northern blot hybridization.
Southern and Northern blot probes
The b-actin probe was a 2.0 kb cDNA (Clontech). Probes pAKV5 and pEco have been described (Nakamura et al., 1996a,b) . p57BXH2A was a 700 bp PCR fragment generated from the¯anking DNA from clone p57BXH2. Probe p57ET47 was a 103 bp exon trapped from p57 P1. The human intron probe was synthesized by PCR from genomic DNA. Human ESTs were derived from IMAGE consortium clones. Full length 1.9 kb human and mouse Evi27 cDNAs were used in all probes and were labeled with a 32 P-dCTP using the Prime It II labeling kit (Stratagene).
DNA sequencing
DNA sequencing was performed using the PRISM Ready Reaction DyeDeoxy Terminator Cycle Sequencing Kit (Perkin Elmer) on the ABI Model 373A DNA Sequencer (Applied Biosystems). Sequence primers were either the T3, T7 sequencing primers or synthetic oligomers derived from previously determined sequence.
Immunohistochemistry
Cells were washed once in PBS, resuspended in PBS and subjected to cytocentrifugation at 12006g for 5 ± 10 min. Cells were air dried for 15 ± 20 min, rinsed in PBS and drained well but not allowed to dry. Cells were ®xed in fresh 4% paraformaldehyde for 10 min followed by two washes in PBS, then permeabilized by incubation in acetone for 30 s at RT. Slides were rinsed in PBS with four changes over 5 min. Cells were blocked with 5% goat serum 30 min at RT. The polyclonal rabbit anti-EVI27 antibody, #2954, was anity puri®ed using the Sulfa-Link kit according to manufacturer's instructions (Pierce, Rockford, IL, USA). Antibodies were diluted in 1 M HEPES buer containing 0.15 N NaCl. Sixty microliters of the primary antibody solution was added to slides and incubated for 30 min in a humidi®ed chamber at RT. The primary antibody was blocked with 100 mg of Evi27 peptide (Figure 4 ) by incubating for 1 h at RT. This solution was then added to the slides as above. After hybridization the slides were washed three times for 5 min in 16PBD (Oncor). The secondary antibody a rhodamine conjugated goat-antirabbit antibody (Pierce) was diluted in the same buer as the primary antibody and the solution was added to slides for 30 min. Slides were washed 36in PBS for 5 min each. The nuclei were counterstained with DAPI at 1/40 dilution in antifade (Oncor), coverslips added and viewed with an Olympus BX60 epi¯uorescence microscope.
For live cells all procedures were performed on ice. Cells were washed twice in cold PBS, incubated with 3%BSA/3% goat serum for 30 min then stained with either 5 mg of primary anti-Evi27 or normal rabbit IgG for 15 min, washed once in PBS, then stained with a 1 : 20 dilution of FITC conjugated goat anti-rabbit antibody (Vector Laboratories) for 15 min, and washed once and resuspended in cold PBS. Cells were placed on slides by cytocentrifugation and were allowed to air dry for 15 min at RT. The nuclei were counterstained with DAPI and visualized as above.
Western blotting
Cells were harvested at logarithmic growth stage and washed 26in 1 XPBS. Cells were resuspended in extraction buer (16PBS (pH 7.2), 10 mg/ml Aprotinin (0.1 unit/ml), 10 mg/ml Leupeptin, 1 mM PMSF) at 10 6 cells/100 ml. Protein was extracted by the freeze-thaw method. The solid phase was removed by centrifugation at 12 000610 min at 48C. The aqueous phase was collected concentrated and quanti®ed using the BCA assay kit (Pierce). Protein separating gels were precast (Novex, San Diego, CA, USA). Protein (50 ± 100 mg) was mixed 1 : 1 with sample buer (26) (Novex), denatured for 15 min, cooled to RT and loaded. Gels were run for 2 ± 3 h at 200 V with cooling (60 W initially) in 16running buer (25 mM Tris, 192 mM glycine, 0.1% SDS at pH 8.3). Protein was transferred to Hybond-C super membrane (Amersham Pharmacia Biotech) using an electrophoretic blotting system (CBS Scienti®c Co. Del Mar, CA, USA) in 16transfer buer (48 mM Tris, 39 mM glycine, 20% methanol) at 100 V for 5 ± 6 h. The Western blot was processed as described (WesternBreeze kit, Novex, San Diego, CA, USA).
Computer DNA and protein sequence analysis
Sequence homology searches were conducted at the protein level using the National Center for Biotechnology Information and the BLAST network service. The DNA and protein sequence alignments and protein motif sequence searches were performed using MacVector (Oxford Molecular Group, Beaverton, OR, USA) and pSORT (Nakai and Kanehisa, 1992) .
